GE Healthcare launched SenoBright in 2010 in Europe and some countries in Asia, and the technology is already in use in mammography centers in France, Spain, Italy, Belgium, Germany, Austria, and Japan. LeGrand says excitement is growing in the United States and that she expects there to be early adopters of CESM. Clinical research continues, with further consideration regarding training and enhancements to the technology as well as thoughts of combining this with other modalities, such as tomosynthesis.
It’s that same principle—highlighting what’s most important—behind the introduction of SenoBright, GE Healthcare’s contrast-enhanced spectral mammography (CESM) technology. SenoBright, which received FDA 510(k) clearance in October 2011, produces contrast-enhanced images of the breast using an X-ray contrast agent and a dual-energy acquisition technique.
Mammography - Medical Clinical Policy Bulletins | Aetna
With CESM, radiologists receive two mammographic images: one that looks like the standard mammogram and a second image that shows the contrast-enhanced areas that can help locate lesions. CESM reduces image noise, not only highlighting lesions but also helping reduce false-positives, according to GE Healthcare. In early clinical trials, CESM discovered more cancerous lesions and accurately measured the size and location of lesions to help plan surgery and treatment.